Literature DB >> 6146348

Pharmacodynamic correlates of modified absorption: studies with lormetazepam.

D M Pierce, R A Franklin, T V Harry, A N Nicholson.   

Abstract

The bioavailability, pharmacokinetics, and effects on performance of lormetazepam (1 mg) have been compared using soft gelatin capsule and tablet formulations. Lormetazepam was more rapidly absorbed from the soft gelatin capsule (tmax = 1.0 +/- 0.2 h) than from the tablet (tmax = 2.4 +/- 0.4 h), and the plasma concentration-time curve for the capsule was shifted to the left. Bioavailability and elimination kinetics did not differ between the formulations. The number of substitutions in the digit symbol test was reduced between 0.5 and 1.5 h for both formulations (P less than 0.001), but the degree of impairment at 0.5 h was greater after the capsule than after the tablet (P less than 0.01). Visuo-motor co-ordination was impaired from 0.5 to 1.5 h after the tablet and the capsule (P less than 0.01), and extended to 5.5 h after the tablet (P less than 0.05). These observations reflect the differences in the plasma concentration-time curves.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6146348      PMCID: PMC1463588          DOI: 10.1111/j.1365-2125.1984.tb05018.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Bioavailability of temazepam in soft gelatin capsules.

Authors:  L M Fuccella
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

3.  Pharmacokinetics of the hypnotic benzodiazepine, temazepam.

Authors:  P Bittencourt; A Richens; P A Toseland; J F Wicks; A N Latham
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

4.  Hypnotic activity and effects on performance of lormetazepam and camazepam--analogues of temazepam.

Authors:  A N Nicholson; B M Stone
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

5.  The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans. I. Absorption, distribution, elimination and metabolism of lormetazepam-5-14C.

Authors:  M Hümpel; V Illi; W Milius; H Wendt; M Kurowski
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

6.  Kinetics and biotransformation of lormetazepam. II. Radioimmunologic determinations in plasma and urine of young and elderly subjects: first-pass effect.

Authors:  M Hümpel; B Nieuweboer; W Milius; H Hanke; H Wendt
Journal:  Clin Pharmacol Ther       Date:  1980-11       Impact factor: 6.875

  6 in total
  5 in total

Review 1.  Hypnotics. Their place in therapeutics.

Authors:  A N Nicholson
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

Review 2.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

Review 3.  Pharmacological treatment of insomnia.

Authors:  M Maczaj
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 4.  An assessment of short-acting hypnotics.

Authors:  W B Mendelson; B Jain
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

5.  Repeated dose effects of lormetazepam and flurazepam upon driving performance.

Authors:  K A Brookhuis; E R Volkerts; J F O'Hanlon
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.